Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FMS
stocks logo

FMS

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
5.09B
+6.75%
0.383
+19.39%
5.13B
+7.71%
0.427
+22%
4.75B
-6.51%
0.461
+12.44%
Estimates Revision
The market is revising No Change the revenue expectations for Fresenius Medical Care AG (FMS) for FY2025, with the revenue forecasts being adjusted by -0% over the past three months. During the same period, the stock price has changed by 10.28%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.32%
In Past 3 Month
Stock Price
Go Up
up Image
+10.28%
In Past 3 Month
3 Analyst Rating
up Image0
Wall Street analysts forecast FMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMS is 36.19 USD with a low forecast of 28.90 USD and a high forecast of 49.66  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
1 Sell
Hold
up Image0
Current: 26.810
sliders
Low
28.90
Averages
36.19
High
49.66
up Image0
Current: 26.810
sliders
Low
28.90
Averages
36.19
High
49.66
Citi
Neutral
maintain
2025-06-05
Reason
Citi
Price Target
2025-06-05
maintain
Neutral
Reason
Citi raised the firm's price target on Fresenius Medical to EUR 52.50 from EUR 46.50 and keeps a Neutral rating on the shares.
Morgan Stanley
Underweight
maintain
2025-05-15
Reason
Morgan Stanley
Price Target
2025-05-15
maintain
Underweight
Reason
Morgan Stanley raised the firm's price target on Fresenius Medical to EUR 43 from EUR 41 and keeps an Underweight rating on the shares.
Truist
Hold
maintain
$25 -> $30
2025-05-12
Reason
Truist
Price Target
$25 -> $30
2025-05-12
maintain
Hold
Reason
Truist raised the firm's price target on Fresenius Medical to $30 from $25 and keeps a Hold rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Truist Securities
David Macdonald
Hold
Maintains
$23 → $25
2025-01-06
Reason
Truist Securities
David Macdonald
Price Target
$23 → $25
2025-01-06
Maintains
Hold
Reason
Truist Securities
David Macdonald
Hold
Maintains
$22 → $23
2024-10-07
Reason
Truist Securities
David Macdonald
Price Target
$22 → $23
2024-10-07
Maintains
Hold
Reason
Truist raised the firm's price target on Fresenius Medical to $23 from $22 and keeps a Hold rating on the shares as part of a broader research note on Healthcare Services. The firm is introducing 2026 estimates and 2025 quarterly estimates across several verticals while also adjusting its model estimates on select names, the analyst tells investors in a research note.
Truist Securities
David Macdonald
Hold
Maintains
$24 → $22
2024-07-31
Reason
Truist Securities
David Macdonald
Price Target
$24 → $22
2024-07-31
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Fresenius Medical Care AG (FMS.N) is 8.57, compared to its 5-year average forward P/E of 14.72. For a more detailed relative valuation and DCF analysis to assess Fresenius Medical Care AG 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
14.72
Current PE
8.57
Overvalued PE
18.12
Undervalued PE
11.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
7.83
Current EV/EBITDA
6.83
Overvalued EV/EBITDA
8.79
Undervalued EV/EBITDA
6.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
0.76
Current PS
0.74
Overvalued PS
1.00
Undervalued PS
0.51

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

FMS News & Events

Events Timeline

(ET)
2025-06-17
07:14:46
Fresenius Medical launches its new FME Reignite strategy
select
2025-02-24 (ET)
2025-02-24
08:02:33
Fresenius Medical divesting select laboratory assets to Quest Diagnostics
select
2024-12-18 (ET)
2024-12-18
06:06:07
Cara Therapeutics, Tvardi Therapeutics enter definitive merger agreement
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
06-18Benzinga
Aurora Cannabis, Bitdeer Technologies Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

  • Stock Market Overview: U.S. stock futures rose this morning, with the Dow gaining over 50 points, while several stocks, including Aurora Cannabis Inc., saw significant declines in pre-market trading following disappointing earnings reports.

  • Notable Stock Movements: Aurora Cannabis shares fell 20.1% after reporting a quarterly loss, alongside other companies like CERo Therapeutics and Vince Holding Corp, which also experienced substantial drops in their stock prices.

Preview
4.5
06-18Benzinga
Fresenius Medical Care Launches Value-Based Care Segment, Eyes Growth Through Innovation, Efficiency

  • Strategic Roadmap and Financial Goals: Fresenius Medical Care AG introduced the FME Reignite roadmap to enhance its core business and innovation, targeting mid-teens operating income margins by 2030 and aiming for €1.05 billion in sustainable savings through the expanded FME25+ program by 2027.

  • Product Launch and Market Impact: The company plans to launch its 5008X machine for high-volume hemodiafiltration in the U.S. starting in 2025, with clinical evidence supporting improved patient outcomes, while also reporting strong earnings that exceeded market expectations despite a recent decline in stock price.

Preview
4.5
06-17NASDAQ.COM
Fresenius Medical Care Reveals FME Reignite Strategy; Announces EUR 1 Bln Share Buyback

  • Fresenius Medical Care's New Strategy: The company launched its FME Reignite strategy, focusing on operational excellence, sustainable innovation, and a strong employee-centric culture through three pillars: Reignite the Core, Reignite Growth and Innovation, and Reignite Our Culture.

  • Financial Initiatives and Goals: Fresenius plans a 30-40% dividend payout, a €1 billion share buyback program starting in 2025, and aims for mid-teens operating income margins by 2030, while extending its cost-saving initiative to achieve €1.05 billion in sustainable savings by 2027.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Fresenius Medical Care AG (FMS) stock price today?

The current price of FMS is 26.81 USD — it has decreased -0.48 % in the last trading day.

arrow icon

What is Fresenius Medical Care AG (FMS)'s business?

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.

arrow icon

What is the price predicton of FMS Stock?

Wall Street analysts forecast FMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMS is 36.19 USD with a low forecast of 28.90 USD and a high forecast of 49.66 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Fresenius Medical Care AG (FMS)'s revenue for the last quarter?

Fresenius Medical Care AG revenue for the last quarter amounts to 5.13B USD, increased 0.04 % YoY.

arrow icon

What is Fresenius Medical Care AG (FMS)'s earnings per share (EPS) for the last quarter?

Fresenius Medical Care AG. EPS for the last quarter amounts to 0.54 USD, increased 107.69 % YoY.

arrow icon

What changes have occurred in the market's expectations for Fresenius Medical Care AG (FMS)'s fundamentals?

The market is revising No Change the revenue expectations for Fresenius Medical Care AG (FMS) for FY2025, with the revenue forecasts being adjusted by -0% over the past three months. During the same period, the stock price has changed by 10.28%.
arrow icon

How many employees does Fresenius Medical Care AG (FMS). have?

Fresenius Medical Care AG (FMS) has 111513 emplpoyees as of June 23 2025.

arrow icon

What is Fresenius Medical Care AG (FMS) market cap?

Today FMS has the market capitalization of 15.73B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free